Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infections in patients with multiple sclerosis: A national cohort study in Sweden
Anna Castelo‐Branco, Flaminia Chiesa, Simona Conte, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 45, pp. 102420-102420
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Stephen L. Hauser, Ludwig Kappos, Xavier Montalbán, et al.
Neurology (2021) Vol. 97, Iss. 16
Open Access | Times Cited: 123
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Anthony T. Reder, Diego Centonze, Maria L. Naylor, et al.
CNS Drugs (2021) Vol. 35, Iss. 3, pp. 317-330
Open Access | Times Cited: 115
Multiple Sclerosis, Disease-Modifying Therapies, and Infections
Annette Langer‐Gould, Jessica B. Smith, Edlin Gonzales, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 6
Open Access | Times Cited: 25
Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases
N. Oksbjerg, Susanne Dam Nielsen, Morten Blinkenberg, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 52, pp. 102988-102988
Open Access | Times Cited: 45
Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
Lutz Achtnichts, Barbara Jakopp, Michael Oberle, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1470-1470
Open Access | Times Cited: 44
Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies — the Polish experience
Agata Czarnowska, Waldemar Brola, Olga Zajkowska, et al.
Neurologia i Neurochirurgia Polska (2021) Vol. 55, Iss. 2, pp. 212-222
Open Access | Times Cited: 34
Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era
Patricia K. Coyle, Anne R. Gocke, Megan Vignos, et al.
Advances in Therapy (2021) Vol. 38, Iss. 7, pp. 3550-3588
Open Access | Times Cited: 34
Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
Stefanie Fischer, Undine Proschmann, Katja Akgün, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 3177-3177
Open Access | Times Cited: 33
MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis
Bassem Yamout, Magd Zakaria, Jihad Inshasi, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 56, pp. 103225-103225
Open Access | Times Cited: 31
An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations
Bülent Kantarcıoğlu, Omer Iqbal, Joseph M. Lewis, et al.
Clinical and Applied Thrombosis/Hemostasis (2022) Vol. 28
Open Access | Times Cited: 21
Risk of serious infections in multiple sclerosis patients by disease course and disability status: Results from a Swedish register-based study
Judith S. Brand, Kelsi A Smith, Fredrik Piehl, et al.
Brain Behavior & Immunity - Health (2022) Vol. 22, pp. 100470-100470
Open Access | Times Cited: 21
Comparative safety of high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis
Katarzyna Śladowska, Paweł Kawalec, Przemysław Holko, et al.
Neurological Sciences (2022) Vol. 43, Iss. 9, pp. 5479-5500
Closed Access | Times Cited: 20
Multiple sclerosis and COVID‐19: The Swedish experience
Anne‐Marie Landtblom, Shala Ghaderi Berntsson, Inger Boström, et al.
Acta Neurologica Scandinavica (2021) Vol. 144, Iss. 3, pp. 229-235
Open Access | Times Cited: 23
Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple Sclerosis Cohort
S Nobile, Philippe Beauchemin
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (2024) Vol. 51, Iss. 6, pp. 811-818
Open Access | Times Cited: 3
Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination
Alessandra Aiello, Serena Ruggieri, Assunta Navarra, et al.
Vaccines (2024) Vol. 12, Iss. 8, pp. 926-926
Open Access | Times Cited: 3
Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment
Susana Otero‐Romero, Adrián Sánchez‐Montalvá, Ángela Vidal‐Jordana
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 3, pp. 285-300
Closed Access | Times Cited: 18
Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs
Berenice Silva, Edgar Carnero Contentti, Jéfferson Becker, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 77, pp. 104840-104840
Closed Access | Times Cited: 8
Infections among individuals with multiple sclerosis, Alzheimer’s disease and Parkinson’s disease
Yihan Hu, Kejia Hu, Huan Song, et al.
Brain Communications (2023) Vol. 5, Iss. 2
Open Access | Times Cited: 7
Infektionen und Multiple Sklerose
Felicita Heidler, Tobias Bopp, Matthias Schwab, et al.
Fortschritte der Neurologie · Psychiatrie (2024)
Closed Access | Times Cited: 2
Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study
Rachel Knapp, F. Hardtstock, Julia Krieger, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 68, pp. 104245-104245
Closed Access | Times Cited: 11
Impact of the COVID-19 Pandemic on Chronic Neurological Disorders: Focus on Patients with Dementia
Natasha Irrera, María Antonietta Barbieri, Gianluca Bagnato, et al.
CNS & Neurological Disorders - Drug Targets (2022) Vol. 21, Iss. 10, pp. 1017-1026
Closed Access | Times Cited: 10
Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials
Asmaa Ahmed Nawar, Aml Mostafa Farid, Rim Wally, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials
Tobias Derfuß, Robert A Bermel, Chien-Ju Lin, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 1
The role of disease modifying therapies in late-onset MS: a Portuguese multicentric characterization study
Patrícia Faustino, Diana Cruz, Catarina Fernandes, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 92, pp. 106153-106153
Closed Access | Times Cited: 1
Vaccination frequency in people newly diagnosed with multiple sclerosis
Sonia Darvishi, Ewan Donnachie, Christiane Gasperi, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 14, pp. 1831-1840
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top